Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Abstract

In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).

Keywords

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyMedicineBetacoronavirusInternal medicineOutbreak

MeSH Terms

Adenosine MonophosphateAdultAgedAlanineAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDrug Administration ScheduleFemaleHospitalizationHumansMaleMiddle AgedOxygen Inhalation TherapyPandemicsPneumoniaViralSARS-CoV-2Treatment OutcomeCOVID-19 Drug Treatment

Affiliated Institutions

Related Publications

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel , Kay M Tomashek , Lori E. Dodd +37 more

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory trac...

2020 New England Journal of Medicine 7559 citations

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen , Di Wu , Wei Guo +17 more

BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is...

2020 Journal of Clinical Investigation 4983 citations

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Bin Cao , Yeming Wang , Danning Wen +62 more

In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illne...

2020 New England Journal of Medicine 5444 citations

Clinical Characteristics of Coronavirus Disease 2019 in China

Wei‐jie Guan , Zhengyi Ni , Yu Hu +34 more

BACKGROUND: Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical charac...

2020 New England Journal of Medicine 30728 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 19
Pages: 1827-1837
Citations: 1419
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1419

OpenAlex

Influential

1116

CrossRef

Cite This

APA Style

                            
                                
                                    Jason D. Goldman, 
                                
                                    David Chien Lye, 
                                
                                    David S.C. Hui
                                
                                et al.
                            
                            (2020). 
                            Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. 
                            New England Journal of Medicine
                            , 383
                            (19)
                            , 1827-1837.
                            https://doi.org/10.1056/nejmoa2015301
                        

Identifiers

DOI: 10.1056/nejmoa2015301
PMID: 32459919
PMCID: PMC7377062

Data Quality

Data completeness: 90%